Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unrelated Cord Blood Transplantation in Poor-Risk Hematological Malignancies
2007-001657-26Phase 2Completed
- Sponsor
- King's College Hospital
- Start
- Nov 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, busulfan, thiotepa and melphalan in Acute Leukaemia, B-cell chronic lymphocytic leukemia (B-CLL), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by King's College Hospital. Primary endpoint: Safety and feasibility of unrelated cord blood transplantation. Started Nov 2007; status: completed.
02
Drugs
fludarabinebusulfanthiotepamelphalan
03
Conditions
Acute LeukaemiaB-cell chronic lymphocytic leukemia (B-CLL)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-001657-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001657-26.